Nipple Sparing Mastectomy gives Breast Cancer Patients A Third Safe Surgery Option

Friday, October 28th, 2011

A new study published in the journal Plastic and Reconstructive Surgery found that some women who need a lumpectomy or mastectomy have a third, perfectly safe option for treatment. The NSM or Nipple Sparing Mastectomy. There are essentially two main paths for surgery when breast cancer is detected. The first ...

Bone Loss Side Effects Of Breast Cancer Medication Prevented By Drug

Monday, October 10th, 2011

A new study has found that an osteoporosis drug protects against the bone damaging side effects of certain breast cancer medications. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that some breast cancer patients could take zoledronic acid in addition to their ...

Mammography Examinations Raise Survival Rates Of Breast Cancer Patients

Monday, October 3rd, 2011

Researchers in Scotland found that mammography examinations improve a breast cancer patient's chance of survival - they reported the findings of their latest study in Health Technology Assessment 2011; vol. 15:34. Every year approximately 45,000 women in the UK are diagnosed with breast cancer. Outcomes in breast cancer ...

Manuka Honey Shows Potential For Radiation-Induced Dermatitis

Wednesday, September 28th, 2011

New findings point to a possible role for manuka honey in the prevention of clinically significant radiation-induced dermatitis in breast cancer patients. The results, from a phase 2 study reported at the 2011 European Multidisciplinary Cancer Congress (EMCC), show that the product may also decrease the duration of dermatitis ...

Afinitor (Everolimus) Prolongs Advanced Breast Cancer Patients’ Progression Free Survival Time

Monday, September 26th, 2011

Afinitor (evelolimus), a Novartis kidney cancer drug, when combined with hormonal therapy doubled breast cancer patients' progression-free survival, and reduced cancer progression risk by 57% compared to exemestane alone, researchers revealed during a Presidential Symposium at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden. Hervé Hoppenot, President, Novartis Oncology, ...